Home Medicine Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty
Article
Licensed
Unlicensed Requires Authentication

Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty

  • Lauren A. Ray ORCID logo EMAIL logo , George J. Eckert and Erica A. Eugster
Published/Copyright: January 11, 2023
Journal of Pediatric Endocrinology and Metabolism
From the journal Journal of Pediatric Endocrinology and Metabolism Volume 36 Issue 3

Abstract

Objectives

The histrelin implant has been used to treat central precocious puberty (CPP) for more than 15 years. Although approved for annual use, limited published reports suggest that a single implant is efficacious well beyond a year. Our objective was to report our long-term experience using a single histrelin implant for more than 12 months in children with CPP.

Methods

We performed a retrospective study of 170 children with central precocious puberty treated with a single histrelin implant for more than 1 year.

Results

Implants were left in situ for an average of 24 months. Pubertal development regressed or remained stable in the vast majority of patients and biochemical suppression was maintained. No correlation between time since an implant was placed and complications such as implant breakage or a second incision was seen.

Conclusions

A single histrelin implant provides excellent pubertal suppression well beyond a year. Extended use of a single histrelin implant should be considered standard of care in children with CPP.

Keywords: central precocious puberty; GnRH analog; histrelin; pubertal suppression
Corresponding author: Lauren A. Ray, MD, Division of Pediatric Endocrinology, Riley Hospital for Children at Indiana University Health, 705 Riley Hospital Drive, Room #5960, Indianapolis, IN, 46202, USA, Phone: 317-944-3889, Fax: 317-944-3882, E-mail:

  1. Research funding: None declared.

  2. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  3. Competing interests: Authors state no conflict of interest.

  4. Informed consent: Not applicable.

  5. Ethical approval: The local Institutional Review Board deemed the study exempt from review.

References

1. Chen, M, Eugster, EA. Central precocious puberty: update on diagnosis and treatment. Paediatr Drugs 2015;17:273–81. https://doi.org/10.1007/s40272-015-0130-8.Search in Google Scholar PubMed PubMed Central

2. Hirsch, HJ, Gillis, D, Strich, D, Chertin, B, Farkas, A, Lindenberg, T, et al.. The histrelin implant: a novel treatment for central precocious puberty. Pediatrics 2005;116:e798–802. https://doi.org/10.1542/peds.2005-0538.Search in Google Scholar PubMed

3. Lewis, KA, Goldyn, AK, West, KW, Eugster, EA. A single histrelin implant is effective for 2 years for treatment of central precocious puberty. J Pediatr 2013;163:1214–6. https://doi.org/10.1016/j.jpeds.2013.05.033.Search in Google Scholar PubMed PubMed Central

4. Rahhal, S, Clarke, WL, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Results of a second year of therapy with the 12-month histrelin implant for the treatment of central precocious puberty. Int J Pediatr Endocrinol 2009;2009:e812517. https://doi.org/10.1155/2009/812517.Search in Google Scholar PubMed PubMed Central

5. Greulich, WW, Pyle, SI. Radiographic atlas of skeletal development of the hand and wrist, 2nd ed. Stanford: Stanford University Press; 1959.10.1097/00000441-195909000-00030Search in Google Scholar

6. Bangalore Krishna, K, Fuqua, JS, Rogol, AD, Klein, KO, Popovic, J, Houk, CP, et al.. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr 2019;91:357–72. https://doi.org/10.1159/000501336.Search in Google Scholar PubMed

7. Lupkin, S. Hormone blocker sticker shock: kids drug costs 8 times more than one for adults; 2020. Available from: https://www.npr.org/sections/health-shots/2020/02/24/808049526/hormone-blocker-sticker-shock-kids-drug-costs-8-times-more-than-one-for-adults [Accessed 29 Jul 2022].Search in Google Scholar

8. Davis, JS, Alkhoury, F, Burnweit, C. Surgical and anesthetic considerations in histrelin capsule implantation for the treatment of precocious puberty. J Pediatr Surg 2014;49:807–10. https://doi.org/10.1016/j.jpedsurg.2014.02.067.Search in Google Scholar PubMed

9. Silverman, LA, Neely, EK, Kletter, GB, Lewis, K, Chitra, S, Terleckyj, O, et al.. Long-term continuous suppression with once-yearly histrelin subcutaneous implants for the treatment of central precocious puberty: a final report of a phase 3 multicenter trial. J Clin Endocrinol Metab 2015;100:2354–63. https://doi.org/10.1210/jc.2014-3031.Search in Google Scholar PubMed PubMed Central

10. Villalta, D, Quintos, JB. Gonadotropin suppression for 7 years after a single histrelin implant for precocious puberty. J Endocr Soc 2022;6:bvab189. https://doi.org/10.1210/jendso/bvab189.Search in Google Scholar PubMed PubMed Central

Received: 2022-10-28
Accepted: 2022-12-30
Published Online: 2023-01-11
Published in Print: 2023-03-28

© 2023 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Thyroid – what is a healthy thyroid function test?
  4. Review
  5. Thyroid storm in pediatrics: a systematic review
  6. Opinion Paper
  7. DSD/intersex: historical context and current perspectives
  8. Original Articles
  9. Predictive value of 6 h postoperative parathyroid hormone level on permanent hypoparathyroidism in pediatric total thyroidectomy: a pilot study
  10. Evaluation of a nurse-led counselling intervention on selected outcome variables for parents of children with congenital adrenal hyperplasia
  11. The relationship between estrogen and subsequent growth restriction among adolescents with heavy menstrual bleeding at menarche
  12. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
  13. Normal bone density but altered geometry in girls with Turner syndrome
  14. Newborn screening for inborn errors of metabolism in a northern Chinese population
  15. Evaluation of serum telomerase activity in normal-weight young girls with polycystic ovary syndrome and its relation to metabolic parameters
  16. Early onset of puberty during COVID-19 pandemic lockdown: experience from two Pediatric Endocrinology Italian Centers
  17. Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty
  18. Short Communications
  19. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty
  20. Relationships among biochemical measures in children with diabetic ketoacidosis
  21. Case Reports
  22. Hyperthyroidism in McCune–Albright Syndrome – a case report
  23. Sexual precocity in the setting of parental use of a compounded testosterone cream: case report and review of the literature
  24. Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis
  25. Identification of a novel mutation in the ALDOB gene in hereditary fructose intolerance
https://doi.org/10.1515/jpem-2022-0557
Keywords for this article
central precocious puberty; GnRH analog; histrelin; pubertal suppression

Articles in the same Issue

  1. Frontmatter
  2. Editorial
  3. Thyroid – what is a healthy thyroid function test?
  4. Review
  5. Thyroid storm in pediatrics: a systematic review
  6. Opinion Paper
  7. DSD/intersex: historical context and current perspectives
  8. Original Articles
  9. Predictive value of 6 h postoperative parathyroid hormone level on permanent hypoparathyroidism in pediatric total thyroidectomy: a pilot study
  10. Evaluation of a nurse-led counselling intervention on selected outcome variables for parents of children with congenital adrenal hyperplasia
  11. The relationship between estrogen and subsequent growth restriction among adolescents with heavy menstrual bleeding at menarche
  12. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment
  13. Normal bone density but altered geometry in girls with Turner syndrome
  14. Newborn screening for inborn errors of metabolism in a northern Chinese population
  15. Evaluation of serum telomerase activity in normal-weight young girls with polycystic ovary syndrome and its relation to metabolic parameters
  16. Early onset of puberty during COVID-19 pandemic lockdown: experience from two Pediatric Endocrinology Italian Centers
  17. Using change in predicted adult height during GnRH agonist treatment for individualized treatment decisions in girls with central precocious puberty
  18. Short Communications
  19. Long-term experience with the use of a single histrelin implant beyond one year in patients with central precocious puberty
  20. Relationships among biochemical measures in children with diabetic ketoacidosis
  21. Case Reports
  22. Hyperthyroidism in McCune–Albright Syndrome – a case report
  23. Sexual precocity in the setting of parental use of a compounded testosterone cream: case report and review of the literature
  24. Intracardiac thrombosis following intravenous zoledronate treatment in a child with steroid-induced osteoporosis
  25. Identification of a novel mutation in the ALDOB gene in hereditary fructose intolerance
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 19.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/jpem-2022-0557/pdf?lang=en
Scroll to top button